Silverarc Capital Management »

Trevi Therapeutics shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Trevi Therapeutics (TRVI) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Trevi Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Trevi Therapeutics held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Trevi Therapeutics by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $2.0M 927k 2.18
2023-06-30 $2.1M 886k 2.39
2023-03-31 $1.6M 886k 1.85
2022-12-31 $1.5M 768k 1.93
2022-09-30 $1.4M 939k 1.54

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Trevi Therapeutics

NEA Management Company
Frazier Life Sciences Management
Viking Global Investors
VR Adviser
Opaleye Management
Vanguard Group
Checkpoint Capital
MAI Wealth Advisors
Tejara Capital
Rosalind Advisors
Landscape Capital Management
Tang Capital Management
Citadel Advisors
J. Goldman & Co
Bnp Paribas Arbitrage, Snc

View all funds holding Trevi Therapeutics